Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Major Depressive Disorder
Interventions
DRUG

Selegiline Transdermal System

EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study

DRUG

Placebo

Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study

Trial Locations (20)

Unknown

Dr. Nelson Handal, Dothan

Dr. Mohammed Bari, National City

Dr. Michael McManus, San Diego

Dr. Elias Sarkis, Gainesville

Dr. Scott Segal, North Miami

Dr. Mary Stedman, Tampa

Dr. Irving Kolin, Winter Park

Dr. Rory Murphy, Overland Park

Dr. Andrew Sediloo, Owensboro

Dr. Bruce Waslick, Springfield

Dr. Christopher Kratochvil, Omaha

Dr. Ann Childress, Las Vegas

Dr. Melissa DelBello, Cincinnati

Dr. Leland Dennis, Oklahoma City

Dr. David Brown, Austin

Dr. Alain Katic, Bellaire

Dr. Graham Emslie, Dallas

Dr. Mary Shemo, Charlottesville

Dr. John Gilliam, Richmond

Dr. Arifulla Khan, Bellevue

Sponsors
All Listed Sponsors
lead

Somerset Pharmaceuticals

INDUSTRY